CG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 1,000 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGONGet Free Report) Director Leonard E. Post sold 1,000 shares of CG Oncology stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total value of $29,660.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Leonard E. Post also recently made the following trade(s):

  • On Friday, December 6th, Leonard E. Post sold 1,000 shares of CG Oncology stock. The shares were sold at an average price of $34.54, for a total value of $34,540.00.

CG Oncology Price Performance

NASDAQ:CGON opened at $27.97 on Wednesday. The business’s fifty day moving average price is $32.28 and its 200 day moving average price is $34.25. CG Oncology, Inc. has a 12 month low of $25.77 and a 12 month high of $50.23.

CG Oncology (NASDAQ:CGONGet Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.30 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. As a group, equities research analysts predict that CG Oncology, Inc. will post -1.32 EPS for the current year.

Institutional Trading of CG Oncology

Several institutional investors have recently modified their holdings of the stock. State Street Corp grew its position in shares of CG Oncology by 73.0% in the 3rd quarter. State Street Corp now owns 1,700,653 shares of the company’s stock valued at $64,166,000 after buying an additional 717,722 shares during the last quarter. Ally Bridge Group NY LLC boosted its stake in CG Oncology by 50.5% in the third quarter. Ally Bridge Group NY LLC now owns 263,266 shares of the company’s stock valued at $9,933,000 after acquiring an additional 88,390 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of CG Oncology by 114.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 379,664 shares of the company’s stock worth $14,325,000 after purchasing an additional 202,262 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of CG Oncology by 876.9% during the third quarter. BNP Paribas Financial Markets now owns 26,660 shares of the company’s stock worth $1,006,000 after purchasing an additional 23,931 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its holdings in shares of CG Oncology by 811.9% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 433,540 shares of the company’s stock valued at $13,687,000 after purchasing an additional 386,000 shares during the last quarter. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Analysts Set New Price Targets

CGON has been the topic of several research reports. Bank of America reissued a “buy” rating and set a $65.00 price target on shares of CG Oncology in a research report on Tuesday, October 8th. UBS Group began coverage on shares of CG Oncology in a research note on Thursday, October 24th. They issued a “buy” rating and a $60.00 price target for the company. Royal Bank of Canada reiterated an “outperform” rating and issued a $66.00 price objective on shares of CG Oncology in a research note on Friday, December 6th. TD Cowen assumed coverage on CG Oncology in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “buy” rating and set a $75.00 price target on shares of CG Oncology in a report on Friday, January 10th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CG Oncology currently has an average rating of “Buy” and a consensus price target of $63.88.

Check Out Our Latest Analysis on CG Oncology

About CG Oncology

(Get Free Report)

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.

Read More

Insider Buying and Selling by Quarter for CG Oncology (NASDAQ:CGON)

Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.